TradeWorx’s Neurocrine Biosciences NBIX Stock Holding History

TradeWorx’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-11,081	Closed	-$103K	–	479
2013 Q4	$103K	Buy	+11,081	New	+$108K	0.04%	442

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TradeWorx's NBIX Position: Q1 2014 in Review

TradeWorx sold out of Neurocrine Biosciences (NBIX) in Q1 2014, closing a stake of 11,081 shares — an estimated $103K sold.

TradeWorx first reported a position in NBIX in Q4 2013 and held it in 1 quarter. The position peaked at $103K in Q4 2013. 121 funds tracked by Wall St. Rank hold NBIX as of Q1 2014.

TradeWorx reported no remaining Neurocrine Biosciences position as of Q1 2014 after selling out during the quarter.
TradeWorx sold 11,081 Neurocrine Biosciences shares in Q1 2014, an estimated $103K.
TradeWorx first reported a position in Neurocrine Biosciences in Q4 2013 and held it in 1 quarter.
TradeWorx's Neurocrine Biosciences position peaked at $103K in Q4 2013.
121 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2014.

Based on TradeWorx's 13F filing for Q1 2014, filed 2 Jun 2014.